BioSpace News Archive

The offering is expected to close on December 12, 2017, subject to customary closing conditions.

Certara announced that Leigh Farrell, PhD, VP of Corporate Strategy and Business Development, is presenting the inaugural Certara New Investigator Awards in association with the ASCEPT.

Under the deal, OAHL will invest up to $2.2 million in tranches to purchase shares of our Capnia subsidiary and as a result of this investment, Capnia will no longer be a wholly-owned subsidiary of Soleno.

With $375,000 in funding from Susan G. Komen, the largest nonprofit funder of breast cancer research (outside of the U.S. government), and other financial support, Dr. Sparano and team at the ECOG-ACRIN Cancer Research Group found that the presence of circulating tumor cells (CTCs) five years after diagnosis was a strong indicator of whether a patient would experience a breast cancer recurrence.

Dr. Alexander’s primary duties will be to advise physicians and regulators on the application of Cannevert’s experimental results with specific cannabis strains to their clinical practice and public policy.

Resources redirected to progress new drug candidates to clinic in H1 2018.

Rigel Pharma today announced that the one-year efficacy and safety results from its FIT Phase 3 clinical program of fostamatinib for chronic or persistent immune thrombocytopenia (ITP) will be featured in an oral presentation at the 2017 ASH Annual Meeting.

In a new study, researchers from Penn Dental Medicine evaluated a new dental material tethered with an antimicrobial compound that can not only kill bacteria but can also resist biofilm growth.

The first warrant will expire on June 30, 2018, and the second on December 31, 2019.

The randomized, open-label, Phase 2 study is expected to enroll approximately 24 patients.